Visible light-controlled carbon monoxide delivery combined with the inhibitory activity of histone deacetylases from a manganese complex for an enhanced antitumor therapy

Hai-Lin Zhang,Ya-Ting Yu,Yi Wang,Qi Tang,Shi-Ping Yang,Jin-Gang Liu
DOI: https://doi.org/10.1016/j.jinorgbio.2021.111354
IF: 4.336
2021-03-01
Journal of Inorganic Biochemistry
Abstract:<p>Multifunctional drugs with synergistic effects have been widely developed to enhance the treatment efficiency of various diseases, such as malignant tumors. Herein, a novel bifunctional manganese(I)-based prodrug [MnBr(CO)<sub>3</sub>(APIPB)] (APIPB = N-(2-aminophen-yl)-4-(1H-imidazo[4,5-f] [1, 10] phenanthrolin-2-yl)benzamide) with inhibitory histone deacetylase (HDAC) activity and light-controlled carbon monoxide (CO) delivery was successfully designed and synthesized. [MnBr(CO)<sub>3</sub>(APIPB)] readily released CO under visible light irradiation (λ &gt; 400 nm) through which the amount of released CO could be controlled by manipulating light power density and illumination time. In the absence of light irradiation, the cytotoxic effect of [MnBr(CO)<sub>3</sub>(APIPB)] on cancer cells was greater than that of the commercially available HDAC inhibitor MS-275. Consequently, with a combination of CO delivery and HDAC inhibitory activity, [MnBr(CO)<sub>3</sub>(APIPB)] showed a remarkably enhanced antitumor effect on HeLa cells (IC<sub>50</sub> = 3.2 μM) under visible light irradiation. Therefore, this approach shows potential for the development of medicinal metal complexes for combined antitumor therapies.</p>
biochemistry & molecular biology,chemistry, inorganic & nuclear
What problem does this paper attempt to address?